+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artemisinin Combination Therapy Market - Global Forecast 2026-2032- Product Image
Artemisinin Combination Therapy Market - Global Forecast 2026-2032- Product Image
New

Artemisinin Combination Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6013910
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Artemisinin Combination Therapy (ACT) continues to serve as a fundamental intervention for malaria, with evolving technological, regulatory, and supply chain dynamics influencing clinical use and commercial strategies. As healthcare demand grows and operational landscapes shift, stakeholders must adapt to maintain access and optimize outcomes.

Market Snapshot: Artemisinin Combination Therapy Market Landscape

The Artemisinin Combination Therapy Market expanded from USD 386.40 million in 2025 to USD 414.27 million in 2026 and is set to grow at a CAGR of 6.69%, reaching USD 608.26 million by 2032. This positive market trajectory reflects rising adoption in malaria treatment protocols, ongoing product innovation, and increased procurement activity across endemic and export-oriented regions.

Scope & Segmentation

This analysis provides a complete breakdown of the Artemisinin Combination Therapy Market through advanced strategic segmentation, helping decision-makers structure product development, commercialization, and sourcing activities efficiently. Major segmentation parameters include:

  • Active Ingredients: Artemether Lumefantrine, Artesunate Amodiaquine, Artesunate Sulfadoxine Pyrimethamine, Dihydroartemisinin Piperaquine. Each compound varies in therapeutic profile and supply requirements.
  • Dosage Forms: Injectable (Intramuscular, Intravenous), Oral Suspension (Granule Sachet, Syrup), Tablet (Co Packaged, Fixed Dose Combination). Formulation choices impact clinical administration and distribution logistics.
  • End Users: Clinics (Private, Public), Homecare (Caregiver Assisted, Self Administration), Hospitals (Private, Public). Segmentation reflects procurement practices, channel preferences, and education requirements.
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, each with unique regulatory, reimbursement, and logistics demands.
  • Patient Groups: Adult, Geriatric, and Pediatric cohorts. Distinctions influence dosing, adherence, and formulation selection.
  • Geographical Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific. Regional factors drive access, regulatory priorities, and commercialization routes.
  • Technology Innovations: Fixed dose combinations, pediatric-friendly formulations, digitized supply chain management, and test-and-treat diagnostic integration support market growth.

Key Takeaways for Decision-Makers

  • Formulation science is supporting the creation of adherence-focused product formats, with innovations in pediatric usability and stability driving new market opportunities.
  • Streamlined regulatory harmonization is lowering barriers for market entry and spurring investment in local and regional manufacturing initiatives.
  • Digitized supply chains and improved visibility tools enhance inventory planning and reduce wastage, underpinning more resilient procurement operations.
  • Pooled purchasing models and outcomes-based contracts are reshaping commercial incentives for both multinational and local suppliers seeking long-term growth.
  • Segmentation by active ingredient and dosage form allows targeted strategies that respond directly to regional healthcare needs, patient prevalence, and operational realities.
  • Collaborations with non-government organizations and donor-funded programs remain central for scaling access in high-burden settings, particularly with pediatric and oral suspension variants.

Tariff Impact on the Artemisinin Combination Therapy Supply Chain

Introduction of United States tariffs in 2025 altered ACT import economics, resulting in shifts toward regional sourcing and onshoring of manufacturing for specific active ingredients and formulations. Suppliers and purchasers now emphasize comprehensive landed cost evaluations—factoring in duties, logistics, and inventory risk—rather than just unit price comparison. These changes prompt longer-term contracts and supply chain diversification to maintain continuous access and manage budget volatility. National malaria programs and procurement agencies continue to adapt inventory planning to mitigate any disruptions linked to tariff measures.

Methodology & Data Sources

This market analysis integrates structured primary interviews with clinical, procurement, and manufacturing leaders, along with secondary reviews of scientific literature, regulatory documents, and public health reports. Triangulation through expert panel validation ensures robust findings. The primary keyword Artemisinin Combination Therapy is used throughout in alignment with best-practice on-page SEO. Segmentation and regional analysis reflect up-to-date industry perspectives.

Why This Report Matters

  • Strategic segmentation and operational insights help inform targeted investment and sourcing decisions for manufacturers, procurement officials, and healthcare providers.
  • Understanding the interplay between technology, regulation, and regional factors enables companies to develop adaptive commercial models and resilient supply chains.
  • Evidence-based analysis supports decision-making for both access-focused non-profits and commercial manufacturers navigating changing policy and economic conditions.

Conclusion

As ACT markets evolve, industry leaders face new opportunities for growth and differentiation by aligning clinical, operational, and sourcing strategies. Ongoing resilience, targeted investment, and collaboration across public and private sectors are essential for ensuring the continued availability and effectiveness of Artemisinin Combination Therapy globally.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Artemisinin Combination Therapy Market, by Active Ingredient
8.1. Artemether Lumefantrine
8.2. Artesunate Amodiaquine
8.3. Artesunate Sulfadoxine Pyrimethamine
8.4. Dihydroartemisinin Piperaquine
9. Artemisinin Combination Therapy Market, by Dosage Form
9.1. Injectable
9.1.1. Intramuscular
9.1.2. Intravenous
9.2. Oral Suspension
9.2.1. Granule Sachet
9.2.2. Syrup
9.3. Tablet
9.3.1. Co Packaged
9.3.2. Fixed Dose Combination
10. Artemisinin Combination Therapy Market, by Patient Group
10.1. Adult
10.2. Geriatric
10.3. Pediatric
11. Artemisinin Combination Therapy Market, by End User
11.1. Clinics
11.1.1. Private
11.1.2. Public
11.2. Homecare
11.2.1. Caregiver Assisted
11.2.2. Self Administration
11.3. Hospitals
11.3.1. Private
11.3.2. Public
12. Artemisinin Combination Therapy Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Artemisinin Combination Therapy Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Artemisinin Combination Therapy Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Artemisinin Combination Therapy Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Artemisinin Combination Therapy Market
17. China Artemisinin Combination Therapy Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Ajanta Pharma Ltd
18.6. Bliss GVS
18.7. Cipla Limited
18.8. Guilin Pharmaceutical Co., Ltd.
18.9. Ipca Laboratories Ltd.
18.10. Kunming Pharmaceutical Corp.
18.11. Mylan NV
18.12. Novartis AG
18.13. Qilu Pharmaceutical Co., Ltd.
18.14. Sanofi SA
18.15. Shin Poong Pharmaceutical Co., Ltd.
18.16. Sun Pharmaceutical Industries Ltd.
18.17. Viatris, Inc.
List of Figures
FIGURE 1. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 152. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 153. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 172. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 173. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 174. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 175. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 176. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 177. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 179. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 180. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 181. AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 197. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 198. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 199. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 200. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 201. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 202. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 204. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 205. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 206. ASEAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 209. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 210. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 211. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 212. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 213. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 214. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 216. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 217. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 218. GCC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 233. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 234. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 235. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 236. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 237. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 238. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 240. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 241. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 242. BRICS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 245. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 246. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 247. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 248. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 249. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 250. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 252. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 253. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 254. G7 ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 257. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 258. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 259. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 260. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 261. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 262. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 264. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 265. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 266. NATO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 267. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
TABLE 282. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 283. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 284. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2032 (USD MILLION)
TABLE 285. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 286. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 287. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 288. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 289. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2032 (USD MILLION)
TABLE 290. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 291. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

  • Ajanta Pharma Ltd
  • Bliss GVS
  • Cipla Limited
  • Guilin Pharmaceutical Co., Ltd.
  • Ipca Laboratories Ltd.
  • Kunming Pharmaceutical Corp.
  • Mylan NV
  • Novartis AG
  • Qilu Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Shin Poong Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris, Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 414.27 Million
Forecasted Market Value ( USD ) by 2032 $ 608.26 Million
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Artemisinin Combination Therapy - Global Strategic Business Report - Product Image

Artemisinin Combination Therapy - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Combination Therapies for Melanoma Market - Global Forecast 2026-2032 - Product Image

Combination Therapies for Melanoma Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Antimalarial Drugs Market - Global Forecast 2026-2032 - Product Image

Antimalarial Drugs Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From

About the Artemisinin Market

Artemisinin is a drug used to treat a variety of infectious diseases, including malaria, schistosomiasis, and filariasis. It is derived from the plant Artemisia annua, and is used in combination with other drugs to increase its effectiveness. Artemisinin is a potent antimalarial drug, and is the most effective treatment for malaria. It is also used to treat other parasitic infections, such as schistosomiasis and filariasis. Artemisinin is available in a variety of forms, including tablets, capsules, and injections. It is also available in combination with other drugs, such as mefloquine, piperaquine, and doxycycline. The drug is generally well tolerated, with few side effects. The Artemisinin market is highly competitive, with many companies offering the drug in various forms. Some of the companies in the market include Novartis, Sanofi, GlaxoSmithKline, Cipla, and Ranbaxy. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.